Pooled data from Phase II and III clinical trials indicate that imetelstat provides consistent clinical benefits to patients with myelodysplastic syndromes (MDS), regardless of prior therapies. The analysis, presented at a recent medical conference, suggests that imetelstat's efficacy in improving transfusion independence (TI) and overall survival (OS) is maintained even in patients who have previously received erythropoiesis-stimulating agents (ESAs). This finding broadens the potential applicability of imetelstat in the treatment of MDS.
The study combined data from multiple trials to assess the impact of prior ESA use on imetelstat's effectiveness. MDS patients treated with imetelstat demonstrated significant improvements in TI duration and OS compared to those who did not receive the drug. Importantly, these benefits were observed both in patients who were ESA-naïve and those who had previously been treated with ESAs.
Consistent Efficacy Across Subgroups
Researchers highlighted the consistency of imetelstat's effects across different patient subgroups. The data suggest that prior ESA therapy does not diminish the drug's ability to induce meaningful clinical responses. This is particularly relevant given the challenges in managing MDS patients who become refractory to or dependent on transfusions after initial ESA treatment.
Implications for MDS Treatment
The findings support imetelstat as a potential treatment option for a broader range of MDS patients, including those with prior treatment history. With limited therapeutic options available for patients who fail or become resistant to initial therapies, imetelstat represents a valuable addition to the treatment armamentarium. Further studies are ongoing to explore the optimal sequencing and combination strategies involving imetelstat in MDS management.
